SCHEMBL838335

SCHEMBL838335

CC(=O)c1cc(C)cc(C(=O)O)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPMT P51580 2/20 0.73
HCAR1 Q9BXC0 1/20 0.61
HCAR2 Q8TDS4 1/20 0.48
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CA5A P35218 2/20 0.46
NR4A1 P22736 1/20 0.45
CNR2 P34972 1/20 0.44
AKR1C3 P42330 2/20 0.43
AKR1C2 P52895 2/20 0.43
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA7 P43166 2/20 0.42
CA9 Q16790 2/20 0.42
CA14 Q9ULX7 2/20 0.42
SRD5A2 P31213 1/20 0.41
NOTUM Q6P988 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetone SCHEMBL27622866 0.90 TPMT (0.80) TPMTHCAR1HCAR2RXRARXRB
SCHEMBL2624954 0.90 TPMT (0.55) TPMTHCAR1HCAR2SMN1; SMN2CA5A
SCHEMBL40661 0.90 TPMT (0.89) TPMTHCAR1HCAR2RXRARXRB
SCHEMBL9350174 0.90 TPMT (0.55) TPMTHCAR1ALDH1A1SMN1; SMN2CA5A
SCHEMBL11762568 0.90 TPMT (0.55) TPMTHCAR1ALDH1A1SMN1; SMN2CA5A
Hydrochloric Acid SCHEMBL4360633 0.87 TPMT (0.84) TPMTHCAR1HCAR2RXRARXRB
SCHEMBL28542863 0.87 TPMT (0.84) TPMTHCAR1HCAR2RXRARXRB
Benzene SCHEMBL27458637 0.87 TPMT (0.84) TPMTHCAR1HCAR2RXRARXRB
Hydrochloric Acid SCHEMBL9622124 0.87 TPMT (0.84) TPMTHCAR1HCAR2RXRARXRB
Ethane SCHEMBL27516125 0.87 TPMT (0.84) TPMTHCAR1HCAR2RXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11840521-B2 Modulators of Mas-related G-protein receptor X4 and related products and methods ESCIENT PHARMACEUTICALS, INC. (US) 2023-12-12 US disclosed
US-20230159474-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS INCYTE CORPORATION 2023-05-25 US disclosed
US-11643399-B2 Modulators of mas-related G-protein receptor X4 and related products and methods ESCIENT PHARMACEUTICALS, INC. (US) 2023-05-09 US disclosed
US-8871015-B2 Non-aqueous pigment dispersions using dispersion synergists AGFA GRAPHICS NV (BE) 2014-10-28 US disclosed
US-20130216480-A1 AMPHIPHILIC POLYMERS AND METHODS OF USE THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2013-08-22 US disclosed
US-20120200650-A1 NON-AQUEOUS PIGMENT DISPERSIONS USING DISPERSION SYNERGISTS AGFA-GEVAERT N.V. (BE) 2012-08-09 US disclosed
US-8143405-B2 Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme Corp (US) 2012-03-27 US disclosed
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20100041667-A1 Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease MERCK SHARP & DOHME LLC 2010-02-18 US disclosed
US-7553831-B2 Beta-secretase inhibitors; inhibiting cleavage of amyloid precursor protein (APP); hydroxy-functional disubstituted amines such as 6-(([[(2S,3S)-4-(3,5-difluorophenyl)-3-((3-[(dipropylamino)carbonyl]benzoyl)amino)-2-hydroxybutyl](ethyl)amino]carbonyl)amino)hexanoic acid ELAN PHARMACEUTICALS, INC. (US) 2009-06-30 US disclosed
US-7498436-B2 Substituted hydroxyethylamines PHARMACIA & UPJOHN COMPANY LLC (US) 2009-03-03 US disclosed
US-20080096942-A1 Substituted Hydroxyethylamines ELAN PHARMACEUTICALS, INC. 2008-04-24 US disclosed
US-7312360-B2 Substituted hydroxyethylamines ELAN PHARMACEUTICALS, INC. (US) 2007-12-25 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-20070213407-A1 Compounds to treat Alzheimer's disease ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC 2007-09-13 US disclosed
US-7214715-B2 Compounds to treat Alzheimer's disease PHARMACIA & UPJOHN (US) 2007-05-08 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11840521-B2 Modulators of Mas-related G-protein receptor X4 and related products and methods MRGPRX4, MRGPRX1, MRGPRX2 TPMT 4211/4885HCAR1 193/4885HCAR2 287/4885
US-20080096942-A1 Substituted Hydroxyethylamines BACE1, BACE2, MME TPMT 962/4885HCAR1 268/4885HCAR2 364/4885
US-20070213407-A1 Compounds to treat Alzheimer's disease PSEN2, PSEN1, CHAT TPMT 779/4885HCAR1 395/4885HCAR2 421/4885
US-11643399-B2 Modulators of mas-related G-protein receptor X4 and related products and methods MRGPRX4, MRGPRX1, MRGPRX2 TPMT 4211/4885HCAR1 193/4885HCAR2 287/4885
US-20130216480-A1 AMPHIPHILIC POLYMERS AND METHODS OF USE THEREOF ABCB4, ANXA3, ANXA5 TPMT 4438/4885HCAR1 1115/4885HCAR2 1560/4885
US-20100041667-A1 Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease BACE1, BACE2, PSEN1 TPMT 639/4885HCAR1 1995/4885HCAR2 2476/4885
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP TPMT 3652/4885HCAR1 1332/4885HCAR2 2468/4885
US-20230159474-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS MRGPRX4, MRGPRX1, MRGPRX2 TPMT 4211/4885HCAR1 193/4885HCAR2 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.